

ASX: ALA

Arovella Therapeutics Limited
ACN 090 987 250

**ASX Release**

11 August 2026

INVESTOR WEBINAR

Arovella Therapeutics Ltd (ASX: ALA), a clinical-stage biotechnology company developing an “off-the-shelf” invariant Natural Killer T (iNKT) cell therapy platform, will host an investor webinar for shareholders and interested parties.

The webinar will provide an update following the Board of Directors’ recent strategic review of the Company, including its priorities for advancing Arovella’s iNKT cell therapy platform, the near-term clinical development of ALA-101 and the Company’s broader opportunity to build shareholder value via pipeline expansion into solid tumour and autoimmune disease indications.

The presentation will be delivered by Chairman, Dr David Williams, and Acting CEO, Dr Nicole van der Weerden, and will also cover progress toward the Company’s Phase 1 first-in-human trial of ALA-101, which is expected to dose the first patient in September 2026.

Details of the investor webinar are below:

Time: 2:00 PM (AEST)

Date: 12 August 2026

Registration: [Click here to register](#)

A recording will be made available via Arovella’s website and social media channels following the event. Thank you to Bell Potter for hosting the webinar.

Release authorised by Arovella Limited Board of Directors.

FURTHER INFORMATION

Dr Nicole Van Der Weerden

Acting Chief Executive Officer

E nvanderweerden@arovella.com

M +61 407 039 983

David Williams

Chairman

E dwilliams@kidder.com.au

M + 61 414 383 594

ASX: ALA

Arovella Therapeutics Limited
ACN 090 987 250



NOTES TO EDITORS:

About Arovella Therapeutics Ltd

Arovella Therapeutics Ltd (ASX: ALA) is focused on developing its invariant natural killer T (iNKT) cell therapy platform licensed from Imperial College London to treat blood cancers, solid tumours, and autoimmune disease. Arovella's lead product is ALA-101. ALA-101 consists of CAR19-iNKT cells that have been modified to produce a Chimeric Antigen Receptor (CAR) that targets CD19. CD19 is an antigen found on the surface of numerous cancer types. iNKT cells also contain an invariant T cell receptor (iTCR) that targets glycolipid bound CD1d, another antigen found on the surface of several cancer types. ALA-101 has had its Investigational New Drug application (IND) accepted by the US FDA and is being developed as an allogeneic cell therapy, which means it can be given from a healthy donor to a patient. Arovella is also expanding into solid tumour treatment through its CLDN18.2-targeting technology licensed from Sparx Group. Arovella will also incorporate its IL-12-TM technology into its solid tumour programs.

Glossary: **iNKT cell** – invariant Natural Killer T cells; **CAR** – Chimeric Antigen Receptor that can be introduced into immune cells to target cancer cells; **TCR** – T cell receptors are a group of proteins found on immune cells that recognise fragments of antigens as peptides bound to MHC complexes; **B-cell lymphoma** – A type of cancer that forms in B cells (a type of immune system cell); **CD1d** – Cluster of differentiation 1, which is expressed on some immune cells and cancer cells; **aGalCer** – alpha-galactosylceramide is a specific ligand for human and mouse natural killer T cells. It is a synthetic glycolipid.

For more information, visit www.arovella.com